KN046 not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
10 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks.”In the company’s words, NCT04474119 on ClinicalTrials.gov
Tested for
Advanced Non-small Cell Lung Cancer (2 trials), Squamous Non-small-cell Lung Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Stage IV Non-small Cell Lung Cancer, Thymic Carcinoma, Advanced HCC, Triple-negative Breast Cancer and 2 more
Main trialPhase 3
“This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.”In the company’s words, NCT04474119 on ClinicalTrials.gov

Other drugs for Advanced Non-small Cell Lung Cancer

All 560 drugs for Advanced Non-small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Unknown 30 Aug 2022 KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer
Phase 3Unknown 30 Apr 2024 KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
Phase 2/3Terminated 13 Feb 2023 KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Phase 2Completed 26 Aug 2021 KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
Phase 2Terminated 30 Jul 2022 KN046 in Patients With Advanced Non-small Cell Lung Cancer
Phase 2Terminated 7 Jul 2023 KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Phase 2Completed 31 Dec 2024 Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Phase 1/2Terminated 30 May 2022 KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1/2Completed 16 Aug 2022 A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Phase 1Completed 3 Jan 2023 KN046 in Subjects With Advanced Solid Tumors and Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KN046

Following is part of Solo: you see every change to KN046 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in